Metabolic Syndrome, Strain, and Reduced Myocardial Function: Multi-Ethnic Study of Atherosclerosis

André Luiz Cerqueira de Almeida, Gisela Teixido-Tura, Eui-Young Choi, Anders Opdahl, Verônica R. S. Fernandes, Colin O. Wu, David A. Bluemke, João A. C. Lima

Johns Hopkins University, Baltimore, MD, USA; Universidade de Feira de Santana, Bahia, Brasil; National Heart, Lung and Blood Institute, Bethesda, MD, USA; National Institutes of Health Clinical Center, National Institute for Biomedical Imaging and Bioengineering, Bethesda, MD - USA

Abstract

Background: Subclinical cardiovascular disease is prevalent in patients with Metabolic Syndrome (MetSyn). Left ventricular (LV) circumferential strain (ε_CC) and longitudinal strain (ε_LL), assessed by Speckle Tracking Echocardiography (STE), are indices of systolic function: shortening is indicated by negative strain, and thus, the more negative the strain, the better the LV systolic function. They have been used to demonstrate subclinical ventricular dysfunction in several clinical disorders.

Objective: We hypothesized that MetSyn is associated with impaired myocardial function, as assessed by STE.

Methods: We analyzed Multi-Ethnic Study of Atherosclerosis (MESA) participants who underwent STE and were evaluated for all MetSyn components.

Results: Among the 133 participants included (women: 63%; age: 65 ± 9 years (mean ± SD)), the prevalence of MetSyn was 31% (41/133). Individuals with MetSyn had lower ε_CC and lower ε_LL than those without MetSyn (-16.3% ± 3.5% vs. -18.4% ± 3.7%, p < 0.01; and -12.1% ± 2.5% vs. -13.9% ± 2.3%, p < 0.01, respectively). The LV ejection fraction (LVEF) was similar in both groups (p = 0.09). In multivariate analysis, MetSyn was associated with less circumferential myocardial shortening as indicated by less negative ε_CC (B = 2.1%, 95% CI: 0.6-3.5, p < 0.01) even after adjusting for age, ethnicity, LV mass, and LVEF. Likewise, presence of MetSyn (B = 1.3%, 95% CI: 0.3-2.2, p < 0.01) and LV mass (B = 0.02%, 95% CI: 0.01-0.03, p = 0.02) were significantly associated with less longitudinal myocardial shortening as indicated by less negative ε_LL after adjustment for ethnicity, LVEF, and creatinine.

Conclusion: Left ventricular ε_CC and ε_LL, markers of subclinical cardiovascular disease, are impaired in asymptomatic individuals with MetSyn and no history of myocardial infarction, heart failure, and/or LVEF < 50%. (Arq Bras Cardiol. 2014; 102(4):327-335)

Keywords: Atherosclerosis; Metabolic X Syndrome; Diabetes Mellitus / mortality; Ventricular Dysfunction / physiopathology; Ethnic Group.

Introduction

Metabolic syndrome (MetSyn) is characterized by a cluster of cardiovascular (CV) risk factors including atherogenic dyslipidemia, abdominal obesity, hyperglycemia, elevated blood pressure, and proinflammatory and prothrombotic state. It affects about 25% of the population, being associated with an increased risk of developing diabetes, CV morbidity and mortality.

Previous studies using carotid intima-media thickness measured with ultrasound, coronary artery calcium, Tei index, and tissue Doppler have shown the presence of subclinical CV disease (CVD) in participants with MetSyn.

Recently, speckle tracking echocardiography (STE) has been introduced as a new non-invasive method for assessing left ventricular (LV) myocardial shortening or strain. The method is angle-independent, does not require contrast agents, and has been validated against sonomicrometry and magnetic resonance imaging (MRI). It has been used to demonstrate subclinical ventricular dysfunction in various clinical disorders.

The purpose of this study was to evaluate the use of STE to assess myocardial strain as a marker of LV systolic function in an asymptomatic population with MetSyn and LV ejection fraction (LVEF) ≥ 50%. We hypothesized that MetSyn is associated with impaired LV circumferential strain (ε_CC), as well as with LV longitudinal strain (ε_LL).

Methods

Study population

The purpose of the Multi-Ethnic Study of Atherosclerosis (MESA), a multicenter population-based study, is to investigate mechanisms underlying the development and
Metabolic syndrome definition

Metabolic syndrome was defined according to revised National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III criteria. Participants having at least three of the following criteria were considered as having MetSyn: fasting plasma glucose (FPG) ≥ 100 mg/dL; triglycerides ≥ 150 mg/dL; HDL-cholesterol < 40 mg/dL in men and < 50 mg/dL in women; abdominal obesity (waist circumference (WC) ≥ 102 cm in men and ≥ 88 cm in women); and blood pressure ≥ 130/85 mm Hg. The revised NCEP definition still includes patients being treated for dyslipidemia, systemic hypertension, or hyperglycemia.

Risk factors

Participants completed standardized medical history questionnaires ascertaining medication use and previous diagnoses and provided samples for quantification of FPG, lipids, and creatinine. Waist circumference was measured at the level of the umbilicus using a standard tape measure. Resting blood pressure was measured three times in a seated position using a Dinamap model Pro 100 automated oscillometric sphygmomanometer (Critikon, Tampa, FL, USA). The average of the last two measurements was used in the analysis. Arterial hypertension was diagnosed using the VII Joint National Committee criteria. Diabetes was defined as a FPG ≥ 126 g/mL or use of insulin or of an oral hypoglycemic agent. Smoking status was defined as current smoking or no smoking.

Echocardiography and speckle tracking

Examinations were performed by expert sonographers, and reviewed off-line by one reader (ALCA). Two-dimensional echocardiograms were recorded during breath-holds using an Artida scanner (Toshiba Medical Systems Corp, Tochigi, Japan) at the time of MESA follow-up evaluation. The images were acquired from the short-axis view of the left ventricle at the papillary muscle level and from the apical 4-chamber view, and stored digitally. The images were recorded using B-mode harmonic images and adjusting transducer frequencies (1.7-3.5 MHz), frame rate (40-80 frames per second), focus (midventricular), sector width (as narrow as possible), sector depth (minimal) and gain in order to optimize myocardial image quality. The echocardiographic recordings were analyzed with STE software (Toshiba 2D Wall Motion Tracking software, Toshiba Medical Systems). The manual counterclockwise tracing of endocardial and epicardial borders in the mid-LV short-axis image at end-systole was followed by automatic drawing of a mid-wall tracking line. A similar approach was made in the 4-chamber recording, starting at the lateral corner of the mitral annulus, at the end-diastole. STE software uses the ‘sum of squared differences’ method to find the most similar speckle pattern of the 2D template in two subsequent frames. Strain (ε, %) was calculated as the change in regional length relative to its end-diastolic length; ε = (L_t – L_0)/L_0×100/L_t, where L_t is the length at time t, and L_0 is the segment length at the onset of QRS. Global ε is reflected myocardial shortening, a more negative value indicates more shortening. The mid-ventricular short axis level and the 4-chamber view of the left ventricle were divided according to the American Society of Echocardiography recommendation. Segments were excluded from analyses due to dropouts, motion artifacts, reverberations, or bad tracking quality due to manual assessment.

Magnetic Resonance Imaging: Tagged MRI protocol and strain measurement

Participants underwent MRI and echocardiography on the same day. Cardiac MRI scan was acquired using 1.5T MR scanners (Signa LX or CVi (GE Medical Systems, Waukesha, WI, USA)). Images were obtained using a segmented k-space and ECG-triggered SPGR pulse sequence. After acquisition of standard scout images, 2- and 4-chamber cine MR images were acquired. Short-axis cine images were then obtained with retrospective gating and temporal resolution of ≤ 50 msec, from above the mitral valve plane to the LV apex. Left ventricular structural parameters (end-systolic and end-diastolic volumes, LV mass) and LVEF were measured using standard commercially available software (MASS 4.2, MEDIS, Leiden, The Netherlands), as previously described. Left ventricular mass index was defined as LV mass divided by body surface area. After completing the standard protocol, three tagged short-axis slices (base to apex) were obtained. Parallel striped tags were prescribed in two orthogonal orientations (0° and 90°) using ECG-triggered fast gradient echo sequence with spatial modulation of magnetization. The parameters for tagged images were as follows: field of view, 40 cm; slice thickness, 7 to 8 mm; repetition time, 6 ms; echo time, 3.0 ms; flip angle, 10° to 12°; phase encoding views, 128 with six phase encoding views per segment; temporal resolution, 35 msec; and tag spacing, 7 mm. Circumferential strain was measured using HARP method embedded in MATLAB software (The MathWorks, Natick, MA, USA).

Reproducibility

Thirty studies were randomly selected for the assessment of intra- and inter-observer variability of ε and ε on STE. To test intra-observer variability, a single observer (ALCA) analyzed the data twice with a minimal interval of 30 days. To test inter-observer variability, a second observer (EYC) analyzed the data without knowing the first observer’s measurements.
Figure 1 – Representative LV $\varepsilon_{cc}$ curve from a participant without MetSyn. Different colors depict different myocardial segments. The white strain curve represents the global circumferential peak strain. ES: end-systole; $\varepsilon_{cc}$: circumferential strain; LV: left ventricle.

Figure 2 – Representative LV $\varepsilon_{ll}$ curve from a participant with MetSyn. Different colors depict different myocardial segments. The white strain curve represents the global longitudinal peak strain. ES: end-systole; $\varepsilon_{ll}$: longitudinal strain; LV: left ventricle; LA: Left atrium; RV: Right ventricle; RA: Right atrium; MV: Mitral valve.
Statistical analysis

Data are shown as mean ± standard deviation (SD) for continuous variables and as proportions for categorical variables. Student’s t test was used to assess differences in continuous variables between the groups studied, whereas chi-square test was used for categorical analysis. Univariate analysis was performed to assess the relationship of $\varepsilon_{CC}$ and $\varepsilon_{LL}$ with the variables of interest. Multiple linear regression (MLR) analysis was performed to study the association between $\varepsilon_{CC}$ assessed on echocardiography and variables with a p value < 0.10 in the univariate analysis, and variables with biological plausibility to interfere with LV strain. The same approach was used for $\varepsilon_{LL}$ measured on echocardiography and for $\varepsilon_{CC}$ measured on tagged MRI. In addition, models of MLR analysis were created, using the stepwise variable selection procedures, to evaluate the potential association of $\varepsilon_{CC}$ and $\varepsilon_{LL}$ on STE and individual MetSyn components, as well as all the possible term interactions between the MetSyn components. Intra-observer and inter-observer variability was assessed by using intraclass correlation coefficient. A two-tailed p value < 0.05 was considered statistically significant for all analyses. Statistical analyses were performed using the SPSS 18 statistical software package (SPSS Inc., Chicago, IL, USA).

Results

Baseline characteristics

Echocardiography was obtained in 162 consecutive MESA participants. Compared to the entire MESA cohort, this study cohort had higher HDL-cholesterol (57.3 ± 19.0 mg/dL versus 52.7 ± 15.6 mg/dL, p < 0.01) and a greater percentage of females (63% versus 47%, p < 0.05). Due to enrollment characteristics of the study site, only black and white study participants were included.

Twenty-six (16%) participants were excluded from the analysis because of poor echocardiographic image quality, and three others (1.9%) because of missing data about at least one of the MetSyn components. No participant was excluded because of a history of MI, HF, or LVEF < 50%. The final study population consisted of 133 participants (women: 63%, mean age = 65 ± 9 years).

The prevalence of MetSyn in this sample was 31% (41 MetSyn in 133 participants). Table 1 lists the clinical and demographic characteristics of the participants according to the MetSyn status. The LVEF measured by use of MRI was 61 ± 5%.

Data reproducibility

The inter-observer and intra-observer intraclass correlation coefficients (ICC) for $\varepsilon_{LL}$ were 0.84 (p < 0.01) and 0.87 (p < 0.01), respectively. Those for $\varepsilon_{CC}$ were 0.86 (p < 0.01) and 0.85 (p < 0.01), respectively.

Metabolic syndrome and LV circumferential strain on STE

Table 2 shows the echocardiographic and MRI data of participants according to the MetSyn status.

The LVEF was similar in both groups (p = 0.09). However, individuals with MetSyn had lower $\varepsilon_{CC}$ on STE than those without MetSyn ($\varepsilon_{CC} = -16.3% ± 3.5%$ versus $-18.4% ± 3.7$, p < 0.01). Men with MetSyn had lower $\varepsilon_{CC}$ on STE as compared with those without MetSyn (-15.5% versus -16.6%, p < 0.01). Women with MetSyn tended to have lower $\varepsilon_{CC}$ (-16.8% versus -18.3%), but with no significance (p = 0.11). The $\varepsilon_{CC}$ was similar in women and men with MetSyn (p > 0.05).

| Variable                        | Without MetSyn (n = 92) Mean ± SD | With MetSyn (n = 41) Mean ± SD | p value |
|---------------------------------|----------------------------------|-------------------------------|---------|
| Age (year)                      | 65 ± 8                           | 66 ± 9                        | 0.27    |
| Creatinine (mg/dL)              | 1.0 ± 0.2                        | 1.0 ± 0.3                     | 0.15    |
| Gender (Female, %)              | 63%                              | 63%                           | 0.97    |
| Ethnicity (Caucasian, %)        | 60%                              | 44%                           | 0.09    |
| Smoking (current, %)            | 8%                               | 10%                           | 0.69    |
| Weight (Kg)                     | 77 ± 17                          | 91 ± 18                       | < 0.01  |
| BMI (Kg/m²)                     | 28 ± 5                           | 32 ± 4                        | < 0.01  |
| Total cholesterol (mg/dL)       | 197 ± 44                         | 177 ± 39                      | 0.01    |
| LDL-cholesterol (mg/dL)         | 116 ± 39                         | 101 ± 36                      | < 0.05  |
| Any lipid-lowering medication (Yes, %) | 28%                          | 47%                           | < 0.05  |
| Waist circumference (cm)*       | 93 ± 13                          | 107 ± 14                      | < 0.01  |
| Glucose (mg/dL)*                | 93 ± 16                          | 107 ± 24                      | < 0.01  |
| Triglycerides (mg/dL)*          | 94 ± 46                          | 151 ± 71                      | < 0.01  |
| HDL-cholesterol (mg/dL)*        | 62 ± 20                          | 46 ± 11                       | < 0.01  |
| Hypertension (Yes, %)           | 42%                              | 80%                           | < 0.01  |

MetSyn: Metabolic Syndrome; SD: standard deviation; BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; *: Metabolic Syndrome component.
In univariate analysis, $\varepsilon_{cc}$ on STE was significantly related to the presence of MetSyn ($p < 0.01$), weight ($p < 0.01$), body mass index (BMI) ($p < 0.05$), and WC ($p < 0.01$) (Table 3). The MLR analysis included variables that were significant in the univariate analysis (MetSyn), as well as variables with biological plausibility to change $\varepsilon_{cc}$, such as LVEF, LV mass, age, and ethnicity. Weight, BMI, and WC were excluded from the model because they are directly or indirectly related to the MetSyn definition. In this model, MetSyn was significantly related to $\varepsilon_{cc}$ even after adjustment for covariates ($B = 2.1\%$; $95\%$ CI: $0.6-3.5$; $p < 0.01$) (Table 3).

In another model of MLR analysis, LVEF, LV mass, age, and ethnicity were maintained, and the MetSyn variable was replaced for all five components of MetSyn. In that case, only WC remained significantly associated with $\varepsilon_{cc}$ ($B = 2.0\%$; $95\%$ CI: $0.7-3.3$; $p < 0.01$, stepwise method). Again, using all the MetSyn components and all the possible interaction terms between them, only WC maintained significance ($B = 2.0\%$; $95\%$ CI: $0.7-3.3$; $p < 0.01$).

The $\varepsilon_{cc}$ measured on echocardiography changed from $-18.7\%$ in participants with ≤ one MetSyn component to $-18.0\%$ in participants with two MetSyn components and to $-16.3\%$ in those with ≥ three MetSyn criteria ($p < 0.01$).

The WC component was present in $95.1\%$ of the participants with MetSyn, while blood pressure, HDL-cholesterol, FPG, and triglycerides were present in $87.8\%$, $61.0\%$, $46.3\%$, and $43.9\%$, respectively. On the other hand, the WC component was present in $45\%$ of the participants without MetSyn.

### Metabolic syndrome and LV circumferential strain on tagged MRI

Similarly to STE results, individuals with MetSyn had lower $\varepsilon_{cc}$ on tagged MRI than those without MetSyn ($\varepsilon_{cc} = -15.8\% \pm 3.3\%$ versus $-17.6\% \pm 2.3\%$, $p < 0.01$) (Table 2).

On univariate analysis, the presence of MetSyn, weight, WC, LVEF, and LV mass were significantly related to $\varepsilon_{cc}$ on tagged MRI. On MLR analysis, both the presence of MetSyn ($B = 1.3\%$; $95\%$ CI: $0.3-2.4$; $p = 0.02$) and LV mass ($B = 0.02\%$; $95\%$ CI: $0.01-0.03$; $p = 0.03$) remained significant.

### Metabolic syndrome and LV longitudinal strain

Individuals with MetSyn had lower $\varepsilon_{ll}$ as compared with those without MetSyn ($-12.1\% \pm 2.5\%$ versus $-13.9\% \pm 2.3\%$, $p < 0.01$) (Table 2). This result was consistent for men and women. The $\varepsilon_{ll}$ was similar in women and men with MetSyn ($p > 0.05$).

On univariate analysis, $\varepsilon_{ll}$ was significantly related to MetSyn, weight, BMI, WC, ethnicity, LV mass, LVEF, creatinine, hypertension status, diabetes status, and triglycerides (Table 4). The MLR analysis included presence of MetSyn, LV mass, LVEF, ethnicity, and creatinine, which were significant in the univariate analysis. Weight, BMI, WC, triglycerides, hypertension, and diabetes status were excluded from the model because they are directly or indirectly related to the MetSyn definition. Presence of MetSyn ($B = 1.3\%$; $95\%$ CI: $0.3-2.2$; $p < 0.01$) and LV mass ($B = 0.02\%$; $95\%$ CI: $0.01-0.03$; $p = 0.02$) were independently related to $\varepsilon_{ll}$ in the model (Table 4). The results were similar when using LV mass indexed by height in meters: presence of MetSyn ($B = 1.3\%$; $95\%$ CI: $0.3-2.2$; $p < 0.01$) and LV mass/height ($B = 0.03\%$; $95\%$ CI: $0.01-0.06$; $p = 0.04$).

In another model of MLR analysis, we maintained LVEF, LV mass, ethnicity, and creatinine, and replaced the MetSyn variable for all five components of MetSyn. With this approach, LV mass ($B = 0.02\%$, $p < 0.01$), ethnicity ($B = 1.0\%$, $p = 0.02$), and FPG component ($B = 1.2\%$, $p = 0.03$) remained as independent predictors of $\varepsilon_{ll}$ (stepwise method). In a model using LV mass, ethnicity, the five MetSyn components, and all the possible interactions between terms (stepwise method), LV mass ($B = 0.02\%$; $95\%$ CI: $0.01-0.03$; $p < 0.01$), ethnicity ($B = 0.9\%$; $95\%$ CI: $0.1-1.8$; $p = 0.03$), and the interaction term WC*FPG ($B = 1.5\%$; $95\%$ CI: $0.3-2.7$; $p = 0.01$) remained significant. The $\varepsilon_{ll}$ changed from $-14.2\%$ in participants with ≤ one MetSyn component, to $-13.4\%$, in participants with two, and to $-12.1\%$ in those with ≥ three MetSyn criteria ($p < 0.01$).

### Discussion

In our data, MetSyn, as defined by NCEP ATP III, was associated with reduced myocardial function as indicated
by an impaired $\varepsilon_{CC}$ and $\varepsilon_{LL}$ in a sample of MESA participants. This result becomes even more important considering that this study sample was constituted by asymptomatic individuals with no history of MI, HF, and/or LVEF<50%. These findings could indicate presence of subclinical CVD in that population. The strength of those relationships was maintained even after adjusting for age, ethnicity, creatinine, LVEF, and LV mass.

Subclinical CVD has been demonstrated in subjects with MetSyn. Gong et al. have used tissue Doppler to analyze $\varepsilon_{LL}$ in Chinese participants with MetSyn. Consistent with our findings in African-American and Caucasian participants, they have demonstrated that mean systolic $\varepsilon_{LL}$ was lower in participants with MetSyn than in controls. In our study, using STE analysis, longitudinal as well as circumferential myocardial functions were reduced, as indicated by lower $\varepsilon_{LL}$ and $\varepsilon_{CC}$ in participants with MetSyn as compared with those without MetSyn. As MetSyn is more prevalent in African-Americans and Caucasians than in the Chinese population, a more general conclusion can be drawn from our study. Furthermore, strain measured by using Doppler has some limitations such as poor reproducibility, angle dependency, and signal noise.

Waist circumference has been cited as a marker of central obesity, carrying a stronger association with health risk indicators. Our data support this concept, because when all five components of MetSyn and all possible interactions between terms were analyzed on MLR analysis, only WC remained significantly associated with $\varepsilon_{CC}$ on STE.

The strain difference between participants with and without MetSyn was small. Differences in circumferential and longitudinal myocardial shortening are typically small, particularly in samples of asymptomatic individuals. Our $\varepsilon_{CC}$ values were higher than $\varepsilon_{LL}$ in concordance with other results. Participants with MetSyn had lower total and LDL-cholesterol than those without MetSyn, probably due to higher usage of lipid-lowering medication.

Our findings indicate that $\varepsilon_{CC}$ was somewhat underestimated on MRI, when compared with $\varepsilon_{CC}$ on STE, independently of the presence of MetSyn. The lower temporal resolution of tagged MRI could explain this difference. Participants with MetSyn had lower total and LDL-cholesterol than those without MetSyn, probably due to higher usage of lipid-lowering medication.

Our findings indicate that $\varepsilon_{CC}$ was somewhat underestimated on MRI, when compared with $\varepsilon_{CC}$ on STE, independently of the presence of MetSyn. The lower temporal resolution of tagged MRI could explain this difference. Participants with MetSyn had lower total and LDL-cholesterol than those without MetSyn, probably due to higher usage of lipid-lowering medication.

The use of STE could help to improve patient care while providing early identification of subclinical disease. Our findings indicate that $\varepsilon_{CC}$ was somewhat underestimated on MRI, when compared with $\varepsilon_{CC}$ on STE, independently of the presence of MetSyn. The lower temporal resolution of tagged MRI could explain this difference.

The use of STE could help to improve patient care while providing early identification of subclinical disease. Our findings indicate that $\varepsilon_{CC}$ was somewhat underestimated on MRI, when compared with $\varepsilon_{CC}$ on STE, independently of the presence of MetSyn. The lower temporal resolution of tagged MRI could explain this difference.

**Limitations**

Because of the cross-sectional design of our study, a causal relationship between MetSyn and strain cannot be established accurately. More studies are necessary to evaluate the clinical implications of our findings.

---

**Table 3 – Univariate and multivariate analysis – Dependent variable: $\varepsilon_{CC}$ on STE**

| Independent variables | Univariate analysis | Multivariate analysis |
|-----------------------|---------------------|-----------------------|
|                       | B coeff (%) | 95%CI | p value | B coeff (%) | 95%CI | p value |
| Presence of MetSyn    | 2.07       | (0.72;3.42) | < 0.01 | 2.06       | (0.59;3.52) | < 0.01 |
| Weight (Kg)           | 0.05       | (0.01;0.08) | < 0.01 | -          | -      | -      |
| Waist circumference (cm) | 0.07     | (0.03;0.11) | < 0.01 | -          | -      | -      |
| BMI (Kg/m²)           | 0.15       | (0.03;0.26) | < 0.05 | -          | -      | -      |
| Age (years)           | 0.02       | (-0.06;0.09) | 0.60 | 0.01       | (-0.07;0.08) | > 0.05 |
| Ethnicity (Caucasian) | -0.57      | (-1.86;0.72) | 0.60 | -0.67      | (-2.17;0.43) | > 0.05 |
| LV mass (g)           | 0.02       | (-0.01;0.04) | 0.17 | 0.01       | (-0.010.03) | > 0.05 |
| LVEF (%)              | -0.03      | (-0.13;0.07) | 0.51 | -0.01      | (-0.11;0.10) | > 0.05 |
| Gender (female)       | 0.17       | (-1.16;1.51) | 0.80 | -          | -      | -      |
| Creatinine (mg/dL)    | -0.18      | (-2.97;2.62) | 0.90 | -          | -      | -      |
| Smoking status (current) | -0.38    | (-2.73;1.97) | 0.75 | -          | -      | -      |
| Hypertension (Yes)    | 0.16       | (-1.14;1.47) | 0.81 | -          | -      | -      |
| Diabetes (Yes)        | 0.80       | (-1.00;2.60) | 0.38 | -          | -      | -      |
| FPG (mg/dL)           | 0.03       | (-0.01;0.06) | 0.09 | -          | -      | -      |
| Total cholesterol (mg/dL) | 0.01   | (-0.01;0.02) | 0.95 | -          | -      | -      |
| LDL-cholesterol (mg/dL) | -0.01  | (-0.02;0.01) | 0.72 | -          | -      | -      |
| HDL-cholesterol (mg/dL) | -0.01  | (-0.04;0.03) | 0.87 | -          | -      | -      |
| Triglycerides (mg/dL) | 0.01       | (-0.01;0.02) | 0.10 | -          | -      | -      |

BMI: body mass index; $\varepsilon_{CC}$: circumferential strain; FPG: fasting plasma glucose; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LV: left ventricle; LVEF: LV ejection fraction; MetSyn: Metabolic Syndrome; MRI: magnetic resonance imaging.
Table 4 – Univariate and multivariate analysis – Dependent variable: ε
t on STE

| Independent variables | Univariate Analysis | Multivariate analysis |
|-----------------------|--------------------|-----------------------|
|                       | B coeff (%)        | 95%CI                 | p value | B coeff (%) | 95%CI | P value |
| Presence of MetSyn    | 1.73               | (0.83;2.64)           | < 0.01  | 1.25        | (0.32;2.19) | < 0.01  |
| Weight (Kg)           | 0.04               | (0.02;0.07)           | < 0.01  | -           | -     | -       |
| Waist circumference (cm) | 0.04           | (0.01;0.07)           | < 0.01  | -           | -     | -       |
| BMI (Kg/m²)           | 0.11               | (0.03;0.18)           | < 0.01  | -           | -     | -       |
| Age (years)           | 0.02               | (-0.03;0.08)          | 0.37    | -           | -     | -       |
| Ethnicity (Caucasian) | 1.11               | (0.24;1.97)           | 0.01    | 0.85        | (-0.0;1.71) | > 0.05  |
| LV mass (g)           | 0.02               | (0.01;0.04)           | < 0.01  | 0.02        | (0.01;0.03) | 0.02   |
| LVEF (%)              | -0.04              | (-0.11;0.03)          | 0.21    | -0.02       | (-0.08;0.05) | > 0.05  |
| Gender (female)       | 0.59               | (-0.31;1.50)          | 0.20    | -           | -     | -       |
| Creatinine (mg/dL)    | 2.10               | (0.23;3.97)           | 0.03    | 0.29        | (-1.74;2.32) | > 0.05  |
| Smoking status (current) | 1.23           | (-0.35;2.82)          | 0.13    | -           | -     | -       |
| Hypertension (Yes)    | 0.97               | (0.10;1.84)           | 0.03    | -           | -     | -       |
| Diabetes (Yes)        | 1.55               | (0.35;2.75)           | 0.01    | -           | -     | -       |
| FPG (mg/dL)           | 0.02               | (-0.01;0.04)          | 0.12    | -           | -     | -       |
| Total cholesterol (mg/dL) | -0.01           | (-0.02;0.01)          | 0.33    | -           | -     | -       |
| LDL-cholesterol (mg/dL) | -0.01            | (-0.02;0.01)          | 0.19    | -           | -     | -       |
| HDL-cholesterol (mg/dL) | -0.01            | (-0.04;0.01)          | 0.26    | -           | -     | -       |
| Triglycerides (mg/dL) | 0.01               | (0.01;0.02)           | 0.02    | -           | -     | -       |

BMI: body mass index; ε
circumferential strain; FPG: fasting plasma glucose; HDL: high-density lipoprotein; LDL: low-density lipoprotein; LV: left ventricle; LVEF: LV ejection fraction; MetSyn: Metabolic Syndrome; MRI: magnetic resonance imaging.
References

1. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007;92(2):399-404.

2. Motillo S, Filion KB, Genest J, Joseph L, Pilotte L, Pierier P, et al. The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-32.

3. Tzou WS, Douglas PS, Srinivasar SR, Bond MG, Tang R, Chen W, et al. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol. 2005;46(3):457-63.

4. Bonora E, Kiech S, Willer JI, Oberhollenzer F, Egger G, Bonadonna RC, et al. Cardiac atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care. 2003;26(4):1251-7.

5. Hassinen M, Kornulainen P, Lakkia TA, Vaisanen SR, Haapala I, Cylling H, et al. Metabolic syndrome and the progression of carotid intima-media thickness in elderly women. Arch Intern Med. 2006;166(4):444-9.

6. Wong ND, Sciammarella-MG, Polk D, Gallagher A, Miranda-Plata L, Whitcomb B, et al. The metabolic syndrome, diabetes, and subclinical atherosclerosis assessed by coronary calcium. J Am Coll Cardiol. 2003;41(9):1547-53.

7. Aijaz B, Ammar KA, Lopez-Jimenez F, Redfield MM, Jacobsen SJ, Rodeheffer RJ. Abnormal cardiac structure and function in the metabolic syndrome: a population-based study. Mayo Clin Proc. 2008;83(12):1350-7.

8. Voulgari C, Moyssakis I, Papazafiropoulou A, Perrea D, Kyriaki D, Katsilambros N, et al. The impact of metabolic syndrome on left ventricular myocardial performance. Diabetes Metab Res Rev. 2010;26(2):121-7.

9. Chinuili M, Devereux RB, Howard BV, Roman MJ, Bella PN, Liu JF, et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol. 2004;93(1):40-4.

10. Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78. Circulation. 2007;116(19):2119-26.

11. Ingelsson E, Sullivan LM, Murabito JM, Fox CS, Benjamin EJ, Polak JF, et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes. 2007;56(6):1718-26.

12. Kullola, Cassidy AE, Pessas PA, Turner ST, Sheedy PF 2nd, Bielas LK. Association between metabolic syndrome and subclinical coronary atherosclerosis in asymptomatic adults. Am J Cardiol. 2004;94(12):1554-8.

13. Gong HP, Tan HW, Fang NN, Song T, Li SH, Zhong M, et al. Impaired left ventricular systolic and diastolic function in patients with metabolic syndrome as assessed by strain and strain rate imaging. Diabetes Res Clin Pract. 2009;83(3):300-7.

14. Ishizu T, Seo Y, Enomoto Y, Sugimori H, Yamamoto M, Machino T, et al. Experimental validation of left ventricular transmural strain gradient with echocardiographic two-dimensional speckle tracking imaging. Eur J Echocardiogr. 2010;11(4):377-85.

15. Amundsen BH, Helle-Valle T, Edvardsen T, Torp H, Crosby J, Lyseggøen E, et al. Noninvasive myocardial strain measurement by speckle tracking echocardiography: validation against sonomicrometry and tagged magnetic resonance imaging. J Am Coll Cardiol. 2006;47(4):789-93.

16. Sivesgaard K, Christensen SD, Nygaard H, Hasenkam JM, Sloth E. Speckle tracking ultrasound is independent of ionisation angle and gain: an in vitro investigation of agreement with sonomicrometry. J Am Soc Echocardiogr. 2009;22(7):852-8.

17. Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr. 2011;12(3):167-205.

18. Dedobbeleer C, Raï M, Donal E, Pandolfo M, Unger P. Normal left ventricular ejection fraction and mass but subclinical myocardial dysfunction in patients with Friedreich’s ataxia. Eur Heart J Cardiovasc Imaging. 2012;13(4):346-52.

19. Vargur J, Seex S, Ackegar N, Canuel M, Ernis N, Karinačoqv Y, et al. Subclinical left ventricular dysfunction in Behcet’s disease assessed by two-dimensional speckle tracking echocardiography. Eur J Echocardiogr. 2011;12(7):536-41.

20. Nakai H, Takeuchi M, Nishikage T, Lang RM, Otsuyi S. Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration. Eur J Echocardiogr. 2009;10(6):926-32.

21. Saha SK, Kiotsekoglou A, Toole RS, Moggridge JC, Nichols KJ, Govind S, et al. Value of two-dimensional speckle tracking and real time three-dimensional echocardiography for the identification of subclinical left ventricular dysfunction in patients referred for routine echocardiography. Eur J Echocardiogr. 2012;29(5):588-97.

22. Ng AC, Delgado V, Bertini M, Antoni ML, van Bommel RM, van Rijnsoever EP, et al. Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: a two-dimensional speckle tracking analysis. Eur Heart J. 2011;32(12):1542-50.

23. Bild DE, Blumke DA, Burke GL, Detrano R, Dicz Roux AV, Folsom AR, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:87-81.

24. Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-8.

25. Nettleton JA, Steffen LM, Mayer-Davis EJ, Jenny NS, Jiang R, Herrington DM, et al. Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr. 2006;83(6):1369-79.

26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52.

27. Ogawa K, Hozumi T, Sugioka K, Matsumura Y, Nishiura M, Kanda R, et al. Usefulness of automated quantitation of regional left ventricular wall motion by a novel method of two-dimensional echocardiographic tracking. Am J Cardiol. 2006;98(11):1531-7.

28. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2(5):358-67.

29. Blumke DA, Kronmal RA, Lima JA, Lit K, Olson J, Burke GL, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. Am J Cardiol. 2008;102(25):2148-55.

30. Castillo E, Osman NF, Rosen BD, El-Shehaby I, Pan L, Jerchow-Herold M, et al. Quantitative assessment of regional myocardial function with MR-tagging in a multi-center study: interserver and intraserver agreement of fast strain analysis with Harmonic Phase (HARP) MRI. J Cardiovasc Magn Reson. 2005;7(5):783-91.

31. Hanekom L, Cho GY, Leano R, Jeffriess L, Marwick TH. Comparison of two-dimensional speckle and tissue Doppler strain measurement during dobutamine stress echocardiography: an angiographic correlation. Eur Heart J. 2007;28(14):1765-72.

32. Shen W, Punyanitya M, Chen J, Gallagher D, Albu J, Pi-Sunyer X, et al. Waist circumference correlates with metabolic syndrome indicators better than percentage fat. Obesity. 2006;14(4):727-36.
33. Rosen BD, Lima JA, Nasir K, Edvardsen T, Folsom AR, Lai S, et al. Lower myocardial perfusion reserve is associated with decreased regional left ventricular function in asymptomatic participants of the multi-ethnic study of atherosclerosis. Circulation. 2006;114(4):289-97.

34. Fernandes VR, Polak JF, Edvardsen T, Carvalho B, Gomes A, Bluemke DA, et al. Subclinical atherosclerosis and incipient regional myocardial dysfunction in asymptomatic individuals: the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2006;47(12):2420-8.

35. Rosen BD, Saad MF, Shea S, Nasir K, Edvardsen T, Burke G, et al. Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic individuals the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2006;47(6):1150-8.

36. Leitman M, Lysiansky M, Lysyansky P, Friedman Z, Tyomkin V, Fuchs T, et al. Circumferential and longitudinal strain in 3 myocardial layers in normal subjects and in patients with regional left ventricular dysfunction. J Am Soc Echocardiogr. 2010;23(1):64-70.

37. Geyer H, Caracciolo G, Abe H, Wilansky S, CARERJ S, Gentile F, et al. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. J Am Soc Echocardiogr. 2010;23(4):351-69.